DDIT3 and follicular lymphoma: In contrast to those studies, a post-hoc analysis performed by our study group of 1172 follicular lymphoma (FL) patients prospectively treated within the same multicentre GLSG1996 and 2000 trials, comparing the effect of rituximab in male and female patients, yielded results in line with the observations of this study: Male patients had a significantly worse outcome than female patients when treated with CHOP (p = 0.0041), but outcome was similar in the R-CHOP cohorts.